Drug Profile
Isavuconazonium - Basilea Pharmaceutica
Alternative Names: AK-1820; ASP-9766; BAL-8557; BAL-8557-000; BAL-8557-002; BAL-9557; Cresemba; isavuconasole; Isavuconazole - Basilea Pharmaceutica; Isavuconazonium chloride; Isavuconazonium sulfate; Isavuconazonium sulphateLatest Information Update: 13 Mar 2024
Price :
$50
*
At a glance
- Originator Basilea Pharmaceutica
- Developer Asahi Kasei Pharma Corp; Astellas Pharma; Avir Pharma; Basilea Pharmaceutica; Hikma Pharmaceuticals; Knight Therapeutics; Memorial Sloan-Kettering Cancer Center; Pfizer
- Class Antifungals; Antineoplastics; Fluorinated hydrocarbons; Inorganic sulfur compounds; Nitriles; Pyridines; Small molecules; Thiazoles; Triazoles
- Mechanism of Action 14-alpha demethylase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes
Highest Development Phases
- Marketed Invasive bronchopulmonary aspergillosis; Mycoses; Zygomycosis
- Phase III Candidiasis
- No development reported Haematological malignancies
Most Recent Events
- 11 Mar 2024 Isavuconazonium - Basilea Pharmaceutica receives Orphan Drug status for Invasive bronchopulmonary aspergillosis (In children) in USA
- 11 Mar 2024 Isavuconazonium - Basilea Pharmaceutica receives Orphan Drug status for Zygomycosis (In children) in USA
- 05 Jan 2024 Basilea Pharmaceutica expects decision for a pediatric label extension from the European Commission for Cresemba® in mid 2024